AU2015375330A1 - Pharmaceutical formulations of xanthine or xanthine derivatives - Google Patents

Pharmaceutical formulations of xanthine or xanthine derivatives Download PDF

Info

Publication number: AU2015375330A1
Authority: AU; Australia
Prior art keywords: group; alkyl; disease; pharmaceutical formulation; disorder
Prior art date: 2015-01-06
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

AU2015375330A

Other languages

English (en)

Other versions

AU2015375330A2 (en

Inventor

Mark Baum

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Harrow Inc

Original Assignee

Imprimis Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-01-06

Filing date

2015-12-29

Publication date

2017-07-13

2015-12-29 Application filed by Imprimis Pharmaceuticals Inc filed Critical Imprimis Pharmaceuticals Inc

2017-07-13 Publication of AU2015375330A1 publication Critical patent/AU2015375330A1/en

2017-10-19 Assigned to ETON PHARMACEUTICALS, INC. reassignment ETON PHARMACEUTICALS, INC. Request for Assignment Assignors: IMPRIMIS PHARMACEUTICALS, INC.

2018-08-16 Assigned to IMPRIMIS PHARMACEUTICALS, INC. reassignment IMPRIMIS PHARMACEUTICALS, INC. Request for Assignment Assignors: ETON PHARMACEUTICALS, INC.

2019-01-31 Assigned to HARROW HEALTH, INC. reassignment HARROW HEALTH, INC. Alteration of Name(s) of Applicant(s) under S113 Assignors: IMPRIMIS PHARMACEUTICALS, INC.

2019-03-27 Priority to AU2019202127A priority Critical patent/AU2019202127A1/en

2019-05-02 Publication of AU2015375330A2 publication Critical patent/AU2015375330A2/en

Status Pending legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Dermatology (AREA)
Ophthalmology & Optometry (AREA)
Inorganic Chemistry (AREA)
Neurology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Oil, Petroleum & Natural Gas (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AU2015375330A 2015-01-06 2015-12-29 Pharmaceutical formulations of xanthine or xanthine derivatives Pending AU2015375330A1 (en)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
AU2019202127A AU2019202127A1 (en)	2015-01-06	2019-03-27	Pharmaceutical formulations of xanthine or xanthine derivatives

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201562100368P	2015-01-06	2015-01-06
US62/100,368		2015-01-06
PCT/US2015/067835 WO2016111885A1 (fr)	2015-01-06	2015-12-29	Formulations pharmaceutiques à base de xanthine ou de dérivés de xanthine

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2019202127A Division AU2019202127A1 (en)	2015-01-06	2019-03-27	Pharmaceutical formulations of xanthine or xanthine derivatives

Publications (2)

Publication Number	Publication Date
AU2015375330A1 true AU2015375330A1 (en)	2017-07-13
AU2015375330A2 AU2015375330A2 (en)	2019-05-02

Family

ID=56285898

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
AU2015375330A Pending AU2015375330A1 (en)	2015-01-06	2015-12-29	Pharmaceutical formulations of xanthine or xanthine derivatives
AU2015101954A Ceased AU2015101954A4 (en)	2015-01-06	2015-12-29	Pharmaceutical formulations of xanthine or xanthine derivatives
AU2019202127A Abandoned AU2019202127A1 (en)	2015-01-06	2019-03-27	Pharmaceutical formulations of xanthine or xanthine derivatives

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
AU2015101954A Ceased AU2015101954A4 (en)	2015-01-06	2015-12-29	Pharmaceutical formulations of xanthine or xanthine derivatives
AU2019202127A Abandoned AU2019202127A1 (en)	2015-01-06	2019-03-27	Pharmaceutical formulations of xanthine or xanthine derivatives

Country Status (8)

Country	Link
US (1)	US20160193213A1 (fr)
EP (1)	EP3242668A4 (fr)
JP (1)	JP2018505156A (fr)
KR (1)	KR20170096201A (fr)
AU (3)	AU2015375330A1 (fr)
CA (1)	CA2973087C (fr)
MX (1)	MX2017008931A (fr)
WO (1)	WO2016111885A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10695351B2 (en) *	2018-07-30	2020-06-30	Harrow Ip, Llc	Pharmaceutical formulations for the treatment of dry eye and methods for fabricating and using thereof
KR102781070B1 (ko) *	2020-12-23	2025-03-20	한국전자기술연구원	코어-쉘 구조를 갖는 양자점 및 이의 제조 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5589171A (en) *	1994-08-22	1996-12-31	Advance Biofactures Of Curacao	Treatment of Dupuytren's disease with collagenase
US6998121B2 (en) *	2003-01-23	2006-02-14	Milkhaus Laboratory, Inc.	Method of treatment of connective tissue disorders by administration of streptolysin O
WO2004037183A2 (fr) *	2002-10-22	2004-05-06	Harbor-Ucla Research And Education Institute	Procedes d'utilisation d'inhibiteurs de phospodiesterases et modulateurs d'acide nitrique, especes d'oxygene reactives, et metalloproteinases dans le traitement de la maladie de peyronie, de l'arteriosclerose et d'autres maladies fibrotiques
WO2005074913A2 (fr) *	2004-01-30	2005-08-18	Angiotech International Ag	Compositions et procedes pour le traitement de la contracture
WO2009052630A1 (fr) *	2007-10-26	2009-04-30	Pacific Therapeutics Ltd.	Compositions et procédés permettant de traiter des troubles fibroprolifératifs
ES2385239B1 (es) *	2010-09-30	2013-06-19	Proteos Biotech S.L.U.	Uso de colagenasa g recombinante, colagenasa h recombinante y pz-peptidasa recombinante para el tratamiento de enfermedades que cursan con alteraciones del colágeno.
EP2804606B1 (fr) *	2012-01-19	2017-06-28	Hybrid Medical, LLC	Préparations thérapeutiques topiques

2015
- 2015-12-29 EP EP15877361.4A patent/EP3242668A4/fr not_active Withdrawn
- 2015-12-29 WO PCT/US2015/067835 patent/WO2016111885A1/fr not_active Ceased
- 2015-12-29 MX MX2017008931A patent/MX2017008931A/es unknown
- 2015-12-29 JP JP2017535887A patent/JP2018505156A/ja active Pending
- 2015-12-29 US US14/982,322 patent/US20160193213A1/en not_active Abandoned
- 2015-12-29 AU AU2015375330A patent/AU2015375330A1/en active Pending
- 2015-12-29 CA CA2973087A patent/CA2973087C/fr active Active
- 2015-12-29 KR KR1020177021763A patent/KR20170096201A/ko not_active Ceased
- 2015-12-29 AU AU2015101954A patent/AU2015101954A4/en not_active Ceased
2019
- 2019-03-27 AU AU2019202127A patent/AU2019202127A1/en not_active Abandoned

Also Published As

Publication number	Publication date
MX2017008931A (es)	2017-10-19
JP2018505156A (ja)	2018-02-22
AU2015101954A4 (en)	2020-04-30
EP3242668A4 (fr)	2018-09-19
AU2015375330A2 (en)	2019-05-02
CA2973087C (fr)	2021-07-13
WO2016111885A1 (fr)	2016-07-14
CA2973087A1 (fr)	2016-07-14
US20160193213A1 (en)	2016-07-07
EP3242668A1 (fr)	2017-11-15
KR20170096201A (ko)	2017-08-23
AU2019202127A1 (en)	2019-04-18

Publication	Publication Date	Title
AU2022202629B2 (en)	2024-06-13	Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization
TWI663971B (zh)	2019-07-01	猝倒症之治療
JP2016531850A (ja)	2016-10-13	頭痛治療用の鼻腔内ｄｈｅ
CA2595329A1 (fr)	2006-07-27	Utilisation de methylnaltrexone et de composes apparentes pour traiter un dysfonctionnement gastrointestinal post-operatoire
MX2011001410A (es)	2011-04-04	Formulaciones de imiquimod de concentracion de dosificacion inferior y regimenes de dosificacion cortos para tratar verrugas genitales y perianales.
US6387917B1 (en)	2002-05-14	Salts of opioid analgesics, particularly morphine, and methods of using same
AU2019202127A1 (en)	2019-04-18	Pharmaceutical formulations of xanthine or xanthine derivatives
US6187790B1 (en)	2001-02-13	Use of cilostazol for treatment of sexual dysfunction
US10383875B2 (en)	2019-08-20	Pharmaceutical formulations of xanthine or xanthine derivatives, and their use
SK284371B6 (sk)	2005-02-04	Použitie oftalmologickej kompozície obsahujúcej účinné množstvo lokálneho inhibítora anhydrázy kyseliny uhličitej na prípravu liečiva
US20160317552A1 (en)	2016-11-03	Pharmaceutical formulations for treating male sexual dysfunctions
US11185546B2 (en)	2021-11-30	Pharmaceutical formulations for the treatment of dry eye and methods for fabricating and using thereof
NZ733132A (en)		Pharmaceutical formulations of xanthine or xanthine derivatives
CN107007608B (zh)	2021-04-23	I型和ii型糖尿病的治疗
AU2018282741A1 (en)	2019-10-31	Pharmaceutical formulations of xanthine or xanthine derivatives, and their use
US7645765B2 (en)	2010-01-12	Use of moxaverin for treating erectile dysfunction, forms of dementia or diseases associated to an arteriosclerotic occlusion
RU2850978C1 (ru)	2025-11-17	Применение агониста рецептора сфингозин-1-фосфата
US6333327B2 (en)	2001-12-25	Method for the treatment of Multiple Sclerosis
US6426084B1 (en)	2002-07-30	Treatment of sexual dysfunction in certain patient groups
HK40100601A (en)	2024-05-03	Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization
US20060128738A1 (en)	2006-06-15	Treatment of interstitial cystitis using cannabinoid analogs
JPH10101564A (ja)	1998-04-21	鼻炎予防及び／又は治療剤
US20200352938A1 (en)	2020-11-12	Pharmaceutical compositions for treating presbyopia and methods for fabricating thereof
JPWO2016063848A1 (ja)	2017-08-10	抗マラリア剤

Legal Events

Date	Code	Title	Description
2017-10-19	PC1	Assignment before grant (sect. 113)	Owner name: ETON PHARMACEUTICALS, INC. Free format text: FORMER APPLICANT(S): IMPRIMIS PHARMACEUTICALS, INC.
2018-08-16	PC1	Assignment before grant (sect. 113)	Owner name: IMPRIMIS PHARMACEUTICALS, INC. Free format text: FORMER APPLICANT(S): ETON PHARMACEUTICALS, INC.
2019-01-31	HB	Alteration of name in register	Owner name: HARROW HEALTH, INC. Free format text: FORMER NAME(S): IMPRIMIS PHARMACEUTICALS, INC.
2019-05-02	DA3	Amendments made section 104	Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 06 JUL 2017; 19 JUL 2017; 19 DEC 2018 AND 28 MAR 2019 Free format text: THE NATURE OF THE AMENDMENT IS: APPLICATION IS TO PROCEED UNDER THE NUMBER 2015101954